Published Dec 11, 2017

FDA approved.png

On December 08, 2017 Aurobindo received FDA approval for Zoledronic Acid which is a bisphosphonate indicated for treatment of Paget’s disease of bone in men and women.

Zoledronic Acid has an estimated annual market of $17.5 million according to IMS data running through October 2017.